Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 5;8:639892. doi: 10.3389/fmolb.2021.639892

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Yang, Xia, Xu, Liang, Zhuo, Wu, An, Wang, Wang, Li, Zhong, Chen, Jia, Wang and Zhao.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Examples of tumor response to the combination of apatinib and osimertinib in EGFR-positive cases with osimertinib resistance. (A) Partial response of a left lung mass to combination therapy in a patient with TP53 mutation detected post-osimertinib/pre-combined treatment biopsy. This patient remained on treatment at the time of last follow-up. (B) Partial response of a left chest wall mass to combination therapy in a patient with TP53 mutation and ERBB2-amplification detected post-osimertinib/pre-combined treatment biopsy. (C) Progressive disease demonstrated with new hepatic metastases after 1 month of combination treatment in a patient with TP53 and PTEN loss-of-function mutations detected in the post-osimertinib/pre-combined treatment biopsy.